APA (7th ed.) Citation

Lazzaro, C., Bergamaschi, R., Zaffaroni, M., Totaro, R., & Paolicelli, D. (2022). Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing-remitting multiple sclerosis in Italy. Neurological Sciences, 43(8), 4933. https://doi.org/10.1007/s10072-022-06022-x

Chicago Style (17th ed.) Citation

Lazzaro, Carlo, Roberto Bergamaschi, Mauro Zaffaroni, Rocco Totaro, and Damiano Paolicelli. "Cost-utility Analysis of Teriflunomide in Naïve Vs. Previously Treated Patients with Relapsing-remitting Multiple Sclerosis in Italy." Neurological Sciences 43, no. 8 (2022): 4933. https://doi.org/10.1007/s10072-022-06022-x.

MLA (9th ed.) Citation

Lazzaro, Carlo, et al. "Cost-utility Analysis of Teriflunomide in Naïve Vs. Previously Treated Patients with Relapsing-remitting Multiple Sclerosis in Italy." Neurological Sciences, vol. 43, no. 8, 2022, p. 4933, https://doi.org/10.1007/s10072-022-06022-x.